6299-66-7Relevant articles and documents
CATALYTIC CARBOXYLATION OF ACTIVATED ALKANES AND/OR OLEFINS
-
Page/Page column 65; 66; 67, (2018/02/28)
The present invention relates to a method of reacting starting materials with an activating group, namely alkanes carrying a leaving group and/or olefins, with carbon dioxide under transition metal catalysis to give carboxyl group-containing products. It is a special feature of the method of the present invention that the carboxylation predominantly takes place at a preferred position of the molecule irrespective of the position of the activating group. The carboxylation position is either an aliphatic terminus of the molecule or it is a carbon atom adjacent to a carbon carrying an electron withdrawing group. The course of the reaction can be controlled by appropriately choosing the reaction conditions to yield the desired regioisomer.
A facile synthesis of racemic 4-ethyl fatty acids
Liu, Yu-Ping,Guan, Wei,Yin, De-Cai,Tian, Hong-Yu,Sun, Bao-Guo
, p. 492 - 494 (2012/10/29)
The synthesis of racemic 4-ethyl fatty acids is reported. A Grignard reagent was first prepared by 3-chloroalkane reacting with magnesium and then 4-ethyl fatty acid methyl esters were synthesised by coupling the Grignard reagent with methyl 3-bromopropionate in the presence of the catalyst Li 2CuCl4. The 4-ethyl fatty acid methyl esters were saponified and then acidified to give the 4-ethyl fatty acids. The syntheses of 4-ethylhexanoic acid, 4-ethylheptanoic acid, 4-ethyloctanoic acid, 4-ethylnonaoic acid and 4-ethyl decanoic acid are described. The structures of the 4-ethyl fatty acid methyl esters and 4-ethyl fatty acids were confirmed by 1H NMR, 13C NMR and HRMS.
PYRIDAZINONE GLUCOKINASE ACTIVATORS
-
Page/Page column 46-47, (2009/10/30)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.